These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 16166800)

  • 1. Combination therapy of intravenous maxacalcitol and percutaneous ethanol injection therapy lowers serum parathyroid hormone level and calcium x phosphorus product in secondary hyperparathyroidism.
    Tanaka M; Itoh K; Matsushita K; Matsushita K; Fukagawa M
    Nephron Clin Pract; 2006; 102(1):c1-7. PubMed ID: 16166800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of percutaneous ethanol injection therapy for secondary hyperparathyroidism in patients on hemodialysis as evaluated by parathyroid hormone levels according to K/DOQI guidelines.
    Tanaka M; Itoh K; Matsushita K; Matsushita K; Fukagawa M
    Ther Apher Dial; 2005 Feb; 9(1):48-52. PubMed ID: 15828906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time course of change in calcium x phosphorus product after percutaneous ethanol injection therapy.
    Koiwa F; Hasegawa T; Kojima I; Ideura T
    Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii53-7. PubMed ID: 12771302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Percutaneous maxacalcitol injection therapy regresses hyperplasia of parathyroid and induces apoptosis in uremia.
    Shiizaki K; Hatamura I; Negi S; Narukawa N; Mizobuchi M; Sakaguchi T; Ooshima A; Akizawa T
    Kidney Int; 2003 Sep; 64(3):992-1003. PubMed ID: 12911549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term (3 years) prognosis of parathyroid function in chronic dialysis patients after percutaneous ethanol injection therapy guided by colour Doppler ultrasonography.
    Tanaka R; Kakuta T; Fujisaki T; Tanaka S; Sakai H; Kurokawa K; Saito A
    Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii58-61. PubMed ID: 12771303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of percutaneous ethanol injection therapy (PEIT) is related to the number of parathyroid glands in haemodialysis patients with secondary hyperparathyroidism.
    Koiwa F; Kakuta T; Tanaka R; Yumita S
    Nephrol Dial Transplant; 2007 Feb; 22(2):522-8. PubMed ID: 17127701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial.
    Hayashi M; Tsuchiya Y; Itaya Y; Takenaka T; Kobayashi K; Yoshizawa M; Nakamura R; Monkawa T; Ichihara A
    Nephrol Dial Transplant; 2004 Aug; 19(8):2067-73. PubMed ID: 15187195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
    Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S
    Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of weekly percutaneous maxacalcitol injection therapy in patients with secondary hyperparathyroidism.
    Saito A; Matsumoto Y; Oyama Y; Asaka M; Yokoyama H
    Ther Apher Dial; 2010 Feb; 14(1):98-103. PubMed ID: 20438525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A case of secondary hyperparathyroidism with an ectopic intrathyroid gland successfully diagnosed and controlled by percutaneous ethanol injection therapy (PEIT)].
    Tanaka M; Itoh K; Matsushita K; Ogawa A; Hirayama H; Tsunoda N; Yoshizumi K; Naruse M; Nonoguchi H; Tomita K
    Nihon Jinzo Gakkai Shi; 2002 May; 44(4):409-13. PubMed ID: 12073627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical experience with percutaneous ethanol injection therapy in hemodialysis patients with renal hyperparathyroidism.
    Nakamura M; Fuchinoue S; Teraoka S
    Am J Kidney Dis; 2003 Oct; 42(4):739-45. PubMed ID: 14520624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parathyroid interventions for secondary hyperparathyroidism in hemodialyzed patients.
    Onoda N; Kashiwagi T; Nakamura T; Niitsu Y; Omata M; Kurihara S
    Ther Apher Dial; 2005 Aug; 9 Suppl 1():S11-5. PubMed ID: 16109135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Control of parathyroid function in patients with a short history of hemodialysis.
    Nishi H; Sato T; Kurihara T; Kurosawa T; Fukagawa M
    Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
    Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
    Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective comparison of the effects of maxacalcitol and calcitriol in chronic hemodialysis patients with secondary hyperparathyroidism: a multicenter, randomized crossover study.
    Mochizuki T; Naganuma S; Tanaka Y; Iwamoto Y; Ishiguro C; Kawashima Y; Maekawa K; Suda A; Akiba T;
    Clin Nephrol; 2007 Jan; 67(1):12-9. PubMed ID: 17269594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The clinical evaluation of maxacalcitol on therapy for secondary hyperparathyroidism of chronic hemodialysis patients].
    Kasai K; Abe R; Wakabayashi M; Nakamura K; Sawatani S; Wakabayashi T
    Nihon Jinzo Gakkai Shi; 2002; 44(5):464-70. PubMed ID: 12216479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Suitable examination intervals for hemodialysis patients with secondary hyperparathyroidism treated with maxacalcitol].
    Yamada Y; Kumafuji M; Sodeyama T; Suzawa T; Momose M; Tokoo M
    Clin Calcium; 2005 Sep; 15 Suppl 1():144-7. PubMed ID: 16272647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognosis of parathyroid function after successful percutaneous ethanol injection therapy guided by color Doppler flow mapping in chronic dialysis patients.
    Kakuta T; Fukagawa M; Fujisaki T; Hida M; Suzuki H; Sakai H; Kurokawa K; Saito A
    Am J Kidney Dis; 1999 Jun; 33(6):1091-9. PubMed ID: 10352197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism.
    Akizawa T; Akiba T; Hirakata H; Kinugasa E; Tominaga Y; Fukagawa M; Yokoyama K; Zhang W; Linde PG; Suzuki M
    Ther Apher Dial; 2015 Jun; 19(3):225-34. PubMed ID: 25363733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.